Last reviewed · How we verify

D326 and D337

Chong Kun Dang Pharmaceutical · Phase 1 active Small molecule

D326 and D337 is a Small molecule drug developed by Chong Kun Dang Pharmaceutical. It is currently in Phase 1 development. Also known as: CKD-386 Reference2.

At a glance

Generic nameD326 and D337
Also known asCKD-386 Reference2
SponsorChong Kun Dang Pharmaceutical
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about D326 and D337

What is D326 and D337?

D326 and D337 is a Small molecule drug developed by Chong Kun Dang Pharmaceutical.

Who makes D326 and D337?

D326 and D337 is developed by Chong Kun Dang Pharmaceutical (see full Chong Kun Dang Pharmaceutical pipeline at /company/chong-kun-dang-pharmaceutical).

Is D326 and D337 also known as anything else?

D326 and D337 is also known as CKD-386 Reference2.

What development phase is D326 and D337 in?

D326 and D337 is in Phase 1.

Related